Cited by 250Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 88 of the 90 references it cites were found in a registry or an index.

Active and Passive Immunotherapy for Neurodegenerative Disorders

Open access

Brody, David L., Holtzman, David M.·2008·Annual Review of Neuroscience

DOI 10.1146/annurev.neuro.31.060407.125529PMC PMC2561172

Open this paper in CoChat — free account

Abstract

Immunotherapeutic strategies to combat neurodegenerative disorders have galvanized the scientific community since the first dramatic successes in mouse models recreating aspects of Alzheimer disease (AD) were reported. However, initial human trials of active amyloid-beta (Abeta) vaccination were halted early because of a serious safety issue: meningoencephalitis in 6% of subjects. Nonetheless, some encouraging preliminary data were obtained, and rapid progress has been made toward developing alternative, possibly safer active and passive immunotherapeutic approaches for several neurodegenerative conditions. Many of these are currently in human trials for AD. Despite these advances, our understanding of the essential mechanisms underlying the effects seen in preclinical models and human subjects is still incomplete. Antibody-induced phagocytosis of pathological protein deposits, direct antibody-mediated disruption of aggregates, neutralization of toxic soluble proteins, a shift in equilibrium toward efflux of specific proteins from the brain, cell-mediated immune responses, and other mechanisms may all play roles depending on the specific immunotherapeutic scenario.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1146/annurev.neuro.31.060407.125529

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656

Show all 90 references

Sorted by citations

The Amyloid State of Proteins in Human Diseases
Eisenberg, D. S., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,769
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Self-citation
Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,075
The many faces of tau
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Excitotoxicity: Bridge to various triggers in neurodegenerative disorders
Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R. R., & Sharma, P. L. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.032 · Cited by 678
Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
Deane, R., Bell, R. D., Sagare, A. P., & Zloković, B. V. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 559
Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498
Alzheimer’s Disease
de Paula, V. D. J. R., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 466
The benefits and limitations of animal models for translational research in neurodegenerative diseases
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 420
Alzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 363
Transgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad, B. G., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 322
Cell-to-cell transmission of non-prion protein aggregates
Lee, S., Desplats, P., Sigurdson, C. J., Tsigelny, I. F., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.145 · Cited by 317
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T. L., Bruzzone, M. G., & Giaccone, G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 276
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 269
Developing Therapeutic Antibodies for Neurodegenerative Disease
Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 231
Aβ(1–40) forms five distinct amyloid structures whose β-sheet contents and fibril stabilities are correlated
Kodali, R. B., Williams, A. D., Chemuru, S., & Wetzel, R. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.06.023 · Cited by 228
CNS expression of anti‐inflammatory cytokine interleukin‐4 attenuates Alzheimer's disease‐like pathogenesis in APP+PS1 bigenic mice
Kiyota, T., Okuyama, S., Swan, R. J., Jacobsen, M. T., Gendelman, H. E., & Ikezu, T. (2010) · The FASEB Journal · doi:10.1096/fj.10-155317 · Cited by 212
How the Interval between Prime and Boost Injection Affects the Immune Response in a Computational Model of the Immune System
Castiglione, F., Mantile, F., Berardinis, P. D., & Prisco, A. (2012) · Computational and Mathematical Methods in Medicine · doi:10.1155/2012/842329 · Cited by 208
Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193
Targeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid
Weller, R. O., Hawkes, C. A., Kalaria, R. N., Werring, D. J., & Carare, R. O. (2014) · Brain Pathology · doi:10.1111/bpa.12218 · Cited by 186
Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives
Lee, S., Lim, H.-S., Masliah, E., & Lee, H.-J. (2011) · Neuroscience Research · doi:10.1016/j.neures.2011.05.008 · Cited by 190
Re-Engineering Biopharmaceuticals for Delivery to Brain with Molecular Trojan Horses
Pardridge, W. M. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800148t · Cited by 168
Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related Pathology
Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166
Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
Kim, J., Eltorai, A. E. M., Jiang, H., Liao, F., Verghese, P. B., Kim, J., Stewart, F. R., Basak, J. M., & Holtzman, D. M. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121274 · Cited by 160
“…the small fraction of anti-apoE antibodies that enter the brain would bind to apoE in plaques and decrease A accumulation by activating microglia-mediated clearance of A aggregates, similar to what has been described for certain anti-A antibodies (Bard et al., 2000; Brody and Holtzman, 2008).”
Self-citation
Amyloid‐ß‐directed immunotherapy for Alzheimer's disease
Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 161
Amyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155
Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae
Albayram, Ö., Kondo, A., Mannix, R., Smith, C., Tsai, C.-Y., Li, C., Herbert, M. K., Qiu, J., Monuteaux, M. C., Driver, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01068-4 · Cited by 154
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease
Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154
Surgical excision of CNS‐draining lymph nodes reduces relapse severity in chronic‐relapsing experimental autoimmune encephalomyelitis
van Zwam, M., Huizinga, R., Heijmans, N., van Meurs, M., Wierenga‐Wolf, A. F., Melief, M., Hintzen, R. Q., Hart, B. A. ‘., Amor, S., Boven, L. A., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2476 · Cited by 151
Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice
Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., Garcia-Alloza, M., Finn, M. B., Hyman, B. T., Bacskai, B. J., & Holtzman, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4147-08.2008 · Cited by 149
Self-citation
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease
van Olst, L., Simonton, B., Edwards, A. J., Forsyth, A. V., Boles, J. S., Jamshidi, P., Watson, T. H., Shepard, N., Krainc, T., Argue, B. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03574-1 · Cited by 164
Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128
“Certain types of active and passive immunization have resulted in significant side effects such as brain edema and hemorrhages (Brody and Holtzman, 2008).”
BackgroundSelf-citation
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice
Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 130
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease
Agbo, D. B., Wolf, E., Jessen, F., Oechsner, M., Hametner, E., Poewe, W. H., Reindl, M., Oertel, W. H., Noelker, C., Bacher, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b90d1 · Cited by 120
Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114
Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Yamin, G., Ono, K., Inayathullah, M., & Teplow, D. B. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404137 · Cited by 111
Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease
Dodel, R. C., Neff, F., Noelker, C., Pul, R., Du, Y., Bacher, M., & Oertel, W. H. (2010) · Drugs · doi:10.2165/11533070-000000000-00000 · Cited by 113
Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance
Shibuya, Y., Chang, C. C. Y., Huang, L.-H., Bryleva, E. Y., & Chang, T.-Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2567-14.2014 · Cited by 108
Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178707 · Cited by 103
Microglial Activation in Alzheimers Disease
Schlachetzki, J. C. M., & Hüll, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147179 · Cited by 105
Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain
Plog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120922 · Cited by 102
Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APP London Mice
Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 96
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Amyloid-β Immunotherapy for Alzheimers Disease
Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 92
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
Improvement of spatial learning by facilitating large-conductance calcium-activated potassium channel with transcranial magnetic stimulation in Alzheimer's disease model mice
Wang, F., Zhang, Y., Wang, L., Sun, P., Luo, X., Ishigaki, Y., Sugai, T., Yamamoto, R., & Kato, N. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.027 · Cited by 87
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 88
Blood Plasma IgG Fc Glycans are Significantly Altered in Alzheimer's Disease and Progressive Mild Cognitive Impairment
Lundström, S. L., Yang, H., Lyutvinskiy, Y., Rutishauser, D., Herukka, S., Soininen, H. S., & Zubarev, R. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131088 · Cited by 83
Murine models of Alzheimer's disease and their use in developing immunotherapies
Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 84
Peripheral Amyloid-β Levels Regulate Amyloid-β Clearance from the Central Nervous System
Marques, M. A., Kulstad, J. J., Savard, C. E., Green, P. S., Lee, S. P., Craft, S., Watson, G. S., & Cook, D. G. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0964 · Cited by 77
APP transgenic mice: their use and limitations
Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79
Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: Insights and therapeutic approaches from periphery
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
Ghosh, S., Ali, R., & Verma, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124231 · Cited by 79
Soluble amyloid-β, effect on cerebral arteriolar regulation and vascular cells
Dietrich, H. H., Xiang, C., Han, B. H., Zipfel, G. J., & Holtzman, D. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-15 · Cited by 81
Self-citation
Autoimmune and inflammatory mechanisms of CNS damage
Kapadia, M., & Šakić, B. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.008 · Cited by 75
Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice
Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 74
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 76
Potential of the Antibody Against cis–Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury
Lu, K. P., Kondo, A., Albayram, Ö., Herbert, M. K., Liu, H., & Zhou, X. Z. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2027 · Cited by 74
Toward Therapy of Human Prion Diseases
Aguzzi, A., Lakkaraju, A. K., & Frontzek, K. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052745 · Cited by 74
Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
Cattepoel, S., Hanenberg, M., Kulic, L., & Nitsch, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018296 · Cited by 74
Autoantibodies Against Amyloid and Glial-Derived Antigens are Increased in Serum and Cerebrospinal Fluid of Lewy Body-Associated Dementias
Maetzler, W., Berg, D., Synofzik, M., Brockmann, K., Godau, J., Melms, A., Gasser, T., Hörnig, S., & Langkamp, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110221 · Cited by 72
The consequences of mitochondrial amyloid β-peptide in Alzheimer's disease
Muirhead, K. E. A., Borger, E., Aitken, L., Conway, S. J., & Gunn‐Moore, F. J. (2010) · Biochemical Journal · doi:10.1042/bj20091941 · Cited by 68
Nanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 69
Noninvasive Magnetic Resonance Imaging Detection of Cerebral Amyloid Angiopathy-Related Microvascular Alterations Using Superparamagnetic Iron Oxide Particles in APP Transgenic Mouse Models of Alzheimer's Disease: Application to Passive Aβ Immunotherapy
Beckmann, N., Gérard, C., Abramowski, D., Cannet, C., & Staufenbiel, M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4936-10.2011 · Cited by 67
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Pérez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65
Elevated Osteopontin Levels in Mild Cognitive Impairment and Alzheimer's Disease
Sun, Y., Yin, X.-S., Guo, H., Han, R.-K., He, R.-D., & Chi, L. (2013) · Mediators of Inflammation · doi:10.1155/2013/615745 · Cited by 63
Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy
Nitsch, R. M., & Höck, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.013 · Cited by 62
Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders
Neff, F., Wei, X., Noelker, C., Bacher, M., Du, Y., & Dodel, R. C. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.04.010 · Cited by 62
Inflammation and Microglia Actions in Alzheimer’s Disease
Combs, C. K. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9165-3 · Cited by 62
Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease
Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 59
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Alzheimers Disease: Pathological Mechanisms and Recent Insights
Niedowicz, D. M., Nelson, P. T., & Murphy, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376181 · Cited by 62
Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease
Rodríguez-Lebrón, E., Gouvion, C. M., Moore, S. A., Davidson, B. L., & Paulson, H. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.123 · Cited by 54
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
Basi, G. S., Hemphill, S. S., Brigham, E. F., Liao, A., Aubele, D. L., Baker, J., Barbour, R., Bova, M. P., Chen, X., Dappen, M. S., et al. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt60 · Cited by 53
A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer’s disease-related pathophysiology in murine models.
Kallop, D. Y., Meilandt, W. J., Gogineni, A., Easley-Neal, C., Wu, T., Jubb, A. M., Yaylaoglu, M., Shamloo, M., Tessier-Lavigne, M., Scearce-Levie, K., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4963-13.2014 · Cited by 54
Nature and Nurture of Catalytic Antibodies
Paul, S., Planque, S. A., Nishiyama, Y., Hanson, C. V., & Massey, R. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3461-0_5 · Cited by 53
Cognitive recovery by chronic activation of the large-conductance calcium-activated potassium channel in a mouse model of Alzheimer's disease
Wang, L., Kang, H., Li, Y., Shui, Y., Yamamoto, R., Sugai, T., & Kato, N. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.033 · Cited by 51
Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers
Robert, R., Dolezal, O., Waddington, L. J., Hattarki, M. K., Cappai, R., Masters, C. L., Hudson, P. J., & Wark, K. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn052 · Cited by 52
Vaccination as a Therapeutic Approach to Alzheimer's Disease
Wısnıewskı, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 53
Antibody Therapeutics Targeting Aβ and TauPreprint
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 55
Self-citation
Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species
Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 50
APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer’s
Yang, A., Kantor, B., & Chiba‐Falek, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031244 · Cited by 51
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 57
Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease
Laurent, S., Ejtehadi, M. R., Rezaei, M., Kehoe, P. G., & Mahmoudi, M. (2012) · RSC Advances · doi:10.1039/c2ra01374f · Cited by 51
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
Rockenstein, E. M., Ostroff, G. R., Dikengil, F., Rus, F., Mante, M., Florio, J. B., Adame, A., Trinh, I., Kim, C., Overk, C., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1170-17.2017 · Cited by 53
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49
Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease
Kalra, J., & Khan, A. G. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.043 · Cited by 47
Recombinant Antibody Fragments for Neurodegenerative Diseases
Manoutcharian, K., Pérez-Garmendia, R., & Gevorkian, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x01666160930121647 · Cited by 48
Immunotherapy in prion disease
Roettger, Y., Du, Y., Bacher, M., Zerr, I., Dodel, R. C., & Bach, J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.258 · Cited by 44
Alzheimer’s Disease: Drug Discovery
Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 49
Moving towards a vaccine
Holtzman, D. M. (2008) · Nature · doi:10.1038/454418a · Cited by 45
Self-citation
Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?
Bayer, T. A., & Wirths, O. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390857 · Cited by 41

Authors: Brody, D. L., & Holtzman, D. M.
Affiliations: Washington University in St. Louis (US)
ORCID: Brody, David L.
Holtzman, David M.
Venue: Annual Review of Neuroscience
Publisher: Annual Reviews
Published: 2008-07-01
Volume: 31
Issue: 1
Pages: 175-193
ISSN: 0147-006X (ISSN-L)
1545-4126
DOI: 10.1146/annurev.neuro.31.060407.125529
PMC: PMC2561172
OpenAlex: W2100298346
Cited by: 250
References: 90
Citations by year: 2026: 6 · 2025: 10 · 2024: 5 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 6 · 2017: 6 · 2016: 10 · 2015: 13 · 2014: 17 · 2013: 19 · 2012: 22
FWCI: 3.55
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Annual Review of Neuroscience (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5k08ns049237-05)
National Institute on Aging (AG20222, R01AG020222, R01AG013956, R37AG013956, AG13956)
National Institute of Neurological Disorders and Stroke (NS049237, K08-NS049237)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: neurodegenerative diseases, Alzheimer's disease, active immunotherapy, passive immunotherapy, meningoencephalitis, antibody-mediated phagocytosis, cell-mediated immunity, immunotherapy safety
MeSH terms: Animals, Antibodies, Humans, Immunity, Immunization, Passive, Nerve Tissue Proteins, Vaccination, Amyloid beta-Peptides, Immunotherapy, Active, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Active and Passive Immunotherapy for Neurodegenerative Disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks